eXmoor pharma, a cell and gene therapy manufacturing partner, and Virica Biotech Inc., a developer of viral vector enhancers, have announced a collaborative project aimed at improving the production of adeno-associated vectors (AAVs), a critical component of gene therapies.   The project, partially funded through a joint Canada-UK government initiative, seeks to address the high manufacturing costs associated with AAV production and make gene therapies more accessible to patients.   Virica&#...